{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kluge K"],"funding":["Christian Doppler Forschungsgesellschaft","Medical University of Vienna"],"pagination":["2833-2842"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11224100"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["51(9)"],"pubmed_abstract":["<h4>Background</h4>Circulating-tumor DNA (ctDNA) and prostate-specific membrane antigen (PSMA) ligand positron-emission tomography (PET) enable minimal-invasive prostate cancer (PCa) detection and survival prognostication. The present study aims to compare their tumor discovery abilities and prognostic values.<h4>Methods</h4>One hundred thirty men with confirmed PCa (70.5 ± 8.0 years) who underwent [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT (184.8 ± 19.7 MBq) imaging and plasma sample collection (March 2019-August 2021) were included. Plasma-extracted cell-free DNA was subjected to whole-genome-based ctDNA analysis. PSMA-positive tumor lesions were delineated and their quantitative parameters extracted. ctDNA and PSMA PET/CT discovery rates were compared, and the prognostic value for overall survi"],"journal":["European journal of nuclear medicine and molecular imaging"],"pubmed_title":["Comparison of discovery rates and prognostic utility of [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT and circulating tumor DNA in prostate cancer-a cross-sectional study."],"pmcid":["PMC11224100"],"funding_grant_id":["CD10277102"],"pubmed_authors":["Kluge K","Amereller D","Kramer G","Kenner L","Egger G","Einspieler H","Haug A","Haberl D","Grubmuller B","Spielvogel C","Shariat S","Hacker M"],"additional_accession":[]},"is_claimable":false,"name":"Comparison of discovery rates and prognostic utility of [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT and circulating tumor DNA in prostate cancer-a cross-sectional study.","description":"<h4>Background</h4>Circulating-tumor DNA (ctDNA) and prostate-specific membrane antigen (PSMA) ligand positron-emission tomography (PET) enable minimal-invasive prostate cancer (PCa) detection and survival prognostication. The present study aims to compare their tumor discovery abilities and prognostic values.<h4>Methods</h4>One hundred thirty men with confirmed PCa (70.5 ± 8.0 years) who underwent [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT (184.8 ± 19.7 MBq) imaging and plasma sample collection (March 2019-August 2021) were included. Plasma-extracted cell-free DNA was subjected to whole-genome-based ctDNA analysis. PSMA-positive tumor lesions were delineated and their quantitative parameters extracted. ctDNA and PSMA PET/CT discovery rates were compared, and the prognostic value for overall survi","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2025-04-04T12:54:19.812Z","creation":"2025-04-04T12:54:19.812Z"},"accession":"S-EPMC11224100","cross_references":{"pubmed":["38693454"],"doi":["10.1007/s00259-024-06698-7"]}}